



**SUNESIS**

## **Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference**

April 3, 2019

SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the Needham & Company 18<sup>th</sup> Annual Healthcare Conference on Wednesday, April 10, 2019 at 2:10 PM Eastern Time at the Westin Grand Central Hotel in New York City.

A live webcast of the presentation will be available on the Sunesis website at <http://ir.sunesis.com>. A replay will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

### **About Sunesis Pharmaceuticals**

Sunesis is a biopharmaceutical company developing new therapeutics for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies. The Company's proprietary PDK1 inhibitor SNS-510 is in preclinical development. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK, and SGK families. Sunesis is exploring strategic alternatives for vosaroxin, a late-stage investigational product for relapsed or refractory AML. Sunesis also has an interest in the pan-RAF inhibitor TAK-580 which is licensed to Takeda. TAK-580 is in a clinical trial for pediatric low-grade glioma.

For additional information on Sunesis, please visit [www.sunesis.com](http://www.sunesis.com).

SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and Media Inquiries:  
Maeve Conneighton  
Argot Partners  
212-600-1902

Willie Quinn  
Sunesis Pharmaceuticals Inc.  
650-266-3716



**SUNESIS**

Source: Sunesis Pharmaceuticals, Inc.